BRIEF published on 03/25/2026 at 15:16, 1 day 4 hours ago NANOBIOTIX denies takeover rumors Biotechnology Takeover NANOBIOTIX Rumors Nanoparticles
BRIEF published on 03/25/2026 at 15:16, 1 day 4 hours ago NANOBIOTIX Responds to Media Speculation on Takeover Intentions Biotechnology Nanotechnology Takeover Speculation NANOBIOTIX Public Statement
PRESS RELEASE published on 03/25/2026 at 15:11, 1 day 4 hours ago NANOBIOTIX Statement Regarding Recent Media Speculation Nanobiotix issues statement addressing media speculation on public take-over intentions, denying any such plans and highlighting factual inaccuracies in recent reports Media Speculation Statement NANOBIOTIX Public Take-over Factual Inaccuracies
BRIEF published on 03/12/2026 at 21:20, 13 days 22 hours ago Nanobiotix Announces Voting Rights and Share Capital Details Euronext Paris Share Capital Voting Rights Nasdaq NANOBIOTIX
PRESS RELEASE published on 03/12/2026 at 21:15, 13 days 22 hours ago Voting Rights and Shares Capital of the Company Nanobiotix discloses voting rights and shares capital details as of February 28, 2026, on Euronext Paris and Nasdaq markets. Learn about their disruptive therapeutic approaches and global presence Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF published on 02/25/2026 at 22:20, 1 month ago NANOBIOTIX Presents at Key Conferences in March Biotechnology Investor Conferences Cancer Treatments NANOBIOTIX Clinical Advances
BRIEF published on 02/17/2026 at 22:20, 1 month 8 days ago Nanobiotix Announces Updated Voting Rights and Share Capital Euronext Paris Voting Rights Shares Capital Financial Disclosure NANOBIOTIX
PRESS RELEASE published on 02/17/2026 at 22:15, 1 month 8 days ago Voting Rights and Shares Capital of the Company Nanobiotix discloses voting rights and shares capital. The biotech company is listed on Euronext Paris and Nasdaq, focusing on disruptive therapies Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF published on 02/02/2026 at 09:44, 1 month 24 days ago Goldman Sachs reduces its stake in Nanobiotix Euronext Paris Goldman Sachs Threshold Crossing Transfer Of Shares NANOBIOTIX
BRIEF published on 01/26/2026 at 09:56, 2 months ago Goldman Sachs crosses thresholds in Nanobiotix Voting Rights Goldman Sachs Crossing Thresholds NANOBIOTIX Off-market Acquisition
Published on 03/26/2026 at 16:20, 3 hours 27 minutes ago ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 13:00, 6 hours 47 minutes ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 6 hours 47 minutes ago GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 6 hours 48 minutes ago Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 19:20, 27 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 37 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:29, 1 hour 17 minutes ago IEVA GROUP: IEVA Group is listing on Euronext Growth® Paris to accelerate its growth and innovation strategy
Published on 03/26/2026 at 18:17, 1 hour 30 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 07:30, 12 hours 17 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
